USA: New research has revealed that polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), may be an independent predictor of atherosclerotic cardiovascular disease (ASCVD). The primary outcome was a composite of coronary artery disease, cerebrovascular disease, and peripheral artery disease. Analyses were adjusted for multiple cardiovascular risk factors, comorbidities, and medication use. PMOS was associated with a more than fourfold higher risk of ASCVD after adjustment for traditional cardiovascular risk factors (adjusted HR 4.40). Atherosclerotic cardiovascular disease risk in polyendocrine metabolic ovarian syndrome: A nationwide, US, claims-based, retrospective, longitudinal, cohort study.